The Epidemiology and Pathophysiology of Kidney Disease in HFpEF With Obesity
Launched by UNIVERSITY OF MISSISSIPPI MEDICAL CENTER · Jun 26, 2025
Trial Information
Current as of July 24, 2025
Recruiting
Keywords
ClinConnect Summary
This research study is looking at how kidney problems develop and work in people who have obesity and a type of heart failure called HFpEF. HFpEF means the heart has trouble filling with blood properly, so it doesn’t pump as much blood as it should. The study aims to understand how the kidneys handle things like protein and salt in people with both obesity and HFpEF compared to healthy individuals. This information could help doctors find better ways to check and treat these conditions.
Adults between 18 and 75 years old can join if they fit into one of three groups: healthy people with normal weight or mild overweight, people who are obese but don’t have heart failure, and people who are both obese and have HFpEF. To participate, people need to have fairly good kidney function and no serious other illnesses. During the study, participants will likely have tests to measure kidney and heart health, and may be asked questions about their health and habits. It’s important to note that the study excludes people with severe illnesses, recent hospital stays, or certain allergies, and those who cannot stop taking some medications. This study is currently recruiting volunteers who meet these criteria.
Gender
ALL
Eligibility criteria
- • Criteria for Cohort 1: Healthy Participants
- Inclusion Criteria:
- • Adults 18-75 years old
- • Normal kidney function
- • No heart failure
- • BMI 25-30kg/m2
- Exclusion Criteria:
- • Diagnosis of chronic illness
- • eGFR\<60mL/min/1.73m2
- • Pregnancy or breast feeding
- • History of cutaneous or allergic reaction to iodine-based products of contrast dyes
- • Hemoglobin levels \<7mg/dL
- • Acute illness or hospitalization event within 3 months
- • Unable to stop NSAIDs
- • Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism
- • Current use of nicotine or recreational drugs, chronic drinker
- • Criteria for Cohort 2: Obese Participants without HFpEF
- Inclusion Criteria:
- • Adults 18-75 years old
- • eGFR \>= 60 mL/min/1.73m2
- • BMI \> 35 kg/m2
- Exclusion Criteria:
- • Diagnosis of Heart Failure
- • Diagnosis of chronic illness
- • eGFR\<60mL/min/1.73m2
- • Pregnancy or breast feeding
- • History of cutaneous or allergic reaction to iodine-based products of contrast dyes
- • Hemoglobin levels \<7mg/dL
- • Acute illness or hospitalization event within 3 months
- • Unable to stop NSAIDs
- • Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism
- • Current use of nicotine or recreational drugs, chronic drinker
- • Criteria for Cohort 3: HFpEF and Obese Participants
- Inclusion Criteria:
- • Adults 18-75 years old
- • eGFR \>= 60 mL/min/1.73m2
- • BMI \> 35 kg/m2
- • Diagnosis of HFpEF (chart diagnosis, LVEF \> 55% on echo, H2FPEF score 6-9 or HFA-PEFF score 5 or 6
- Exclusion Criteria:
- • NYHA class III/IV
- • Urinary retention screen +
- • Mobility issues
- • History of RRT or kidney transplant
- • Acute illness/hospitalization in the past 3 months
- • History of cancer, chemo, or XRT
- • Pregnant/breastfeeding
- • History of allergies to contrast
- • Hemoglobin \< 7
- • Comorbid conditions: MM, amyloidosis, pheochromocytoma, SCD, metastatic brain lesions, advanced kidney disease, liver dysfunction, endotoxemia, hyperthyroidism
- • Unable to stop NSAIDs
- • Current use of nicotine or recreational drugs, chronic drinker
About University Of Mississippi Medical Center
The University of Mississippi Medical Center (UMMC) is a leading academic medical institution dedicated to advancing healthcare through innovative research, education, and clinical services. As the only academic health science center in the state, UMMC integrates patient care, research, and education to enhance health outcomes and address pressing medical challenges. With a focus on translational research, UMMC conducts a wide range of clinical trials aimed at discovering new treatments and improving patient care across various medical disciplines. Its commitment to excellence in research and collaboration with diverse stakeholders positions UMMC as a pivotal contributor to the advancement of medical science and the wellbeing of communities it serves.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jackson, Mississippi, United States
Patients applied
Trial Officials
Marissa C Tio, MD
Principal Investigator
University of Mississippi Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported